Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres

Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres

Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1–3). Side effects of alemtuzu...

Full description

Bibliographic Details
Main Authors: Anil J. Trindade, Tany Thaniyavarn, Keri Townsend, Robin Klasek, Karen P. Tsveybel, John C. Kennedy, Hilary J. Goldberg, Souheil El-Chemaly
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Immunology
Subjects:
alemtuzumab
chronic lung allograft dysfunction
lung transplantation
short telomeres
chronic rejection
telomere length
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01063/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01063/full

Similar Items